First Wave BioPharma Files 8-K for General Disclosure
Ticker: GRDX · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | First Wave Biopharma, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
**FWBI filed a routine 8-K, no major news.**
AI Summary
First Wave BioPharma, Inc. filed an 8-K on January 4, 2024, to disclose general information, specifically under Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates routine compliance with SEC regulations, confirming the company's current business address at 777 Yamato Road, Suite 502, Boca Raton, Florida, and its trading symbol FWBI on an unspecified exchange. For investors, this filing primarily serves as a confirmation of ongoing regulatory adherence rather than revealing new material financial or operational developments, suggesting a neutral impact on stock valuation unless further details emerge.
Why It Matters
This filing confirms First Wave BioPharma's ongoing compliance with SEC reporting requirements, which is crucial for maintaining investor confidence and market transparency.
Risk Assessment
Risk Level: low — This 8-K is a standard disclosure filing and does not contain information that indicates new or elevated risks.
Analyst Insight
A smart investor would note this as a routine compliance filing and look for more substantive news or financial reports for actionable insights into First Wave BioPharma's performance or strategic direction.
Key Numbers
- $0.0001 — Par Value per Share (The par value of First Wave BioPharma's Common Stock.)
Key Players & Entities
- First Wave BioPharma, Inc. (company) — registrant
- January 4, 2024 (date) — date of earliest event reported and filing date
- 777 Yamato Road, Suite 502, Boca Raton, Florida (address) — principal executive offices
- FWBI (company) — trading symbol
- $0.0001 (dollar_amount) — par value per share of Common Stock
FAQ
What is the purpose of this 8-K filing by First Wave BioPharma, Inc.?
This 8-K filing by First Wave BioPharma, Inc. is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically disclosing information under Regulation FD Disclosure and Financial Statements and Exhibits, as reported on January 4, 2024.
What is the trading symbol for First Wave BioPharma, Inc.?
The trading symbol for First Wave BioPharma, Inc. is FWBI, as stated in the filing under 'Title of each class' for 'Common Stock, par value $0.0001 per share'.
What is the par value of First Wave BioPharma, Inc.'s Common Stock?
The par value of First Wave BioPharma, Inc.'s Common Stock is $0.0001 per share, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
Where are First Wave BioPharma, Inc.'s principal executive offices located?
First Wave BioPharma, Inc.'s principal executive offices are located at 777 Yamato Road, Suite 502, Boca Raton, Florida, 33431, according to the business address provided in the filing.
What is the earliest event reported date for this 8-K filing?
The date of the earliest event reported for this 8-K filing is January 4, 2024, as stated at the beginning of the 'CURRENT REPORT' section.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-01-04 08:22:04
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share FWBI The Nasdaq Capital M
Filing Documents
- tm241946d1_8k.htm (8-K) — 26KB
- tm241946d1_ex99-1.htm (EX-99.1) — 21KB
- 0001104659-24-001157.txt ( ) — 223KB
- fwbi-20240104.xsd (EX-101.SCH) — 3KB
- fwbi-20240104_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240104_pre.xml (EX-101.PRE) — 22KB
- tm241946d1_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 4, 2024, the Company released a letter from James Sapirstein, the Company's Chief Executive Officer, to its shareholders. A copy of the letter is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing or document, except as shall be expressly set forth by specific reference in such a filing or document.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The following Exhibits are being furnished with this Current Report on Form 8-K. Exhibit No. Description 99.1 Press Release, dated January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. First Wave BioPharma, Inc. January 4, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer